All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Fecal microbiota transplantation in high-risk lower GI acute GvHD after allo-HCT
At the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), DeFilipp presented on the feasibility and safety of FMT in high-risk...
What is the latest data from REACH-3 for ruxolitinib treated patients with SR-cGvHD after crossover?
During the 49th Annual Meeting of the EBMT, the GvHD Hub was pleased to speak to Robert Zeiser, Medical Center – University of Freiburg, Freiburg,...
Are you a healthcare professional? What is your specialty?
Please select or type your specialty
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.